Core Viewpoint - LuKang Pharmaceutical (600789) has received the drug registration certificate for Gefitinib tablets and the approval notice for the raw material drug from the National Medical Products Administration, indicating a significant advancement in its oncology product portfolio [1] Company Summary - Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with sensitive EGFR gene mutations [1] - The company has invested approximately 11.1491 million yuan in the research and development of Gefitinib tablets and about 9.9 million yuan in the raw material drug [1] Industry Summary - There are currently 15 existing drug registration numbers for Gefitinib tablets in China, with projected sales of 263 million yuan in 2024 [1]